Spectrin beta chain, non-erythrocytic 2 (SPTBN2)

Spectrin beta chain, non-erythrocytic 2 (SPTBN2) encodes beta-III spectrin, a membrane-associated cytoskeletal scaffolding protein that maintains cellular architecture by linking the plasma membrane to the cytoskeleton[2][3][5]. It is highly expressed in cerebellar Purkinje cells and regulates membrane protein trafficking, notably stabilizing the glutamate transporter EAAT4 at the plasma membrane[3][5]. Pathogenic SPTBN2 mutations cause spinocerebellar ataxia 5 (SCA5) and are associated with neurodegeneration, impaired synaptic plasticity, and motor coordination disorders[2][3]. Aberrant or overexpressed SPTBN2 has been observed in multiple cancers and is linked to poor outcomes, especially in lung adenocarcinoma, pancreatic cancer, bladder cancer, and colorectal cancer[2][4]. In non–small cell lung cancer, SPTBN2 modulates chemoresistance and ferroptosis via interaction with SLC7A11, showing importance in membrane protein localization and cell signaling[3]. SPTBN2 is highly relevant as a disease biomarker and as a candidate therapeutic target in cancer and neurodegenerative disease research[2][3][4][5].

Other names

Beta-III spectrinSpinocerebellar ataxia 5 proteinSCA5SCAR14KIAA0302GTRAP41Glutamate transporter EAAT4-associated protein 41Spectrin beta III sigma 2Spectrin beta chain, brain 2Spectrin non-erythroid beta chain 2

No approved drugs with established mechanism directly targeting SPTBN2; by association, stabilization of EAAT4, modulation of membrane protein localization, influence on metabolic and chemoresistance pathways may be relevant